10-Q: Septerna Secures Major Novo Nordisk GPCR Deal

Septerna, Inc. reports increased losses but secures a transformative collaboration with Novo Nordisk, significantly extending its cash runway and validating its drug discovery platform.

Summary

• Septerna reported a net loss of $24.8 million for the three months ended June 30, 2025, compared to $16.4 million for the same period in 2024, and a net loss of $46.3 million for the six months ended June 30, 2025, up from $30.6 million in 2024.
• Revenue decreased to $0.1 million for Q2 2025 from $0.4 million for Q2 2024, and to $0.3 million for the six months ended June 30, 2025, from $0.7 million in 2024, primarily from research services for Vertex.
• Research and development expenses increased to $22.2 million for Q2 2025 from $15.0 million for Q2 2024, and to $41.5 million for the six months ended June 30, 2025, from $28.2 million in 2024, driven by higher direct costs for clinical and preclinical programs and increased headcount.
• General and administrative expenses rose to $6.9 million for Q2 2025 from $3.4 million for Q2 2024, and to $13.8 million for the six months ended June 30, 2025, from $6.1 million in 2024, due to increased headcount and public company operating costs.
• Cash, cash equivalents, and marketable securities totaled $379.2 million as of June 30, 2025.
• The company entered into a Collaboration and License Agreement with Novo Nordisk A/S on May 13, 2025, which became effective July 1, 2025, following antitrust clearance.
• Under the Novo Nordisk agreement, Septerna received a one-time, non-refundable upfront payment of $195.0 million in July 2025.
• Septerna is eligible to receive up to $498.0 million in research, development, regulatory, and commercial milestone payments for each of the initially four R&D programs, plus escalating, tiered royalties from mid to high single-digits on global net sales.
• Novo Nordisk will reimburse Septerna for 100% of fully burdened costs for research and development activities under the collaboration.
• The SEP-786 clinical study was discontinued in February 2025.
• A $12.5 million milestone payment from Vertex Pharmaceuticals was received in August 2025, related to an asset purchase agreement from September 2023.

Sentiment

Score: 9

Explanation: The transformative collaboration with Novo Nordisk, including significant upfront funding, potential milestones, and full R&D cost coverage for partnered programs, provides substantial validation for Septerna's platform and significantly extends its cash runway. This strategic partnership outweighs the increased operational losses in the current period, positioning the company for strong future growth and de-risking its financial profile.

Positives

• Secured a significant global collaboration and license agreement with Novo Nordisk A/S, validating Septerna's proprietary Native Complex Platform and providing substantial non-dilutive funding.
• Received a $195.0 million upfront payment from Novo Nordisk in July 2025, significantly bolstering liquidity.
• Eligible for substantial future milestone payments up to $498.0 million per R&D program and tiered royalties on global net sales from the Novo Nordisk collaboration, offering significant long-term revenue potential.
• Novo Nordisk will cover 100% of the research and development expenses for the partnered programs, reducing Septerna's financial burden for these key initiatives.
• The company's cash, cash equivalents, and marketable securities of $379.2 million as of June 30, 2025, combined with the Novo Nordisk upfront payment and Vertex milestone, are expected to fund operations at least into 2029, providing a strong cash runway.
• Advancing key pipeline candidates like SEP-631 (MRGPRX2) into clinical development and next-generation oral small molecule PTH1R agonists.

Negatives

• Net loss increased significantly to $24.8 million for Q2 2025 from $16.4 million for Q2 2024, and to $46.3 million for the six months ended June 30, 2025, from $30.6 million in 2024.
• Revenue from research services decreased to $0.1 million for Q2 2025 from $0.4 million for Q2 2024.
• Operating expenses, including research and development and general and administrative, increased substantially year-over-year.
• The SEP-786 clinical study was discontinued in February 2025, indicating a setback for that specific program.

Risks

• Disruptions at the FDA and other government agencies due to staffing, funding shortages, or global health concerns could hinder product development, approval, or commercialization.
• Unfavorable global economic conditions, political instability, and geopolitical events (e.g., tariffs, inflation, supply chain disruptions, bank failures) could adversely affect business, financial condition, and stock price.
• Healthcare legislative reform measures, such as the Inflation Reduction Act of 2022 (IRA) and other cost containment efforts, may negatively impact drug pricing, reimbursement, and profitability.
• Changes in U.S. tax law, including the One Big Beautiful Bill Act (H.R.1) and Section 174 of the IRC, could adversely affect cash flow and financial results, particularly regarding the capitalization and amortization of R&D expenses.
• The company has incurred significant losses since inception and expects to continue incurring losses as it advances product candidates, requiring substantial additional funding beyond current resources.
• The successful development and commercialization of product candidates are highly uncertain, dependent on clinical trial outcomes, regulatory approvals, and market acceptance.

Future Outlook

The company expects to continue incurring significant and increasing expenditures for the next several years as it advances product candidates through preclinical studies and into clinical trials, expands its pipeline, seeks regulatory approvals, and builds commercial infrastructure. It anticipates increased research and development expenses as SEP-631 (MRGPRX2) advances into clinical development and next-generation oral small molecule PTH1R agonists progress. The company believes its current cash, cash equivalents, and marketable securities, combined with the upfront payment from Novo Nordisk and the Vertex milestone payment, will be sufficient to fund operations at least into 2029. Future financing is expected through equity offerings, debt financings, or collaborations.

Management Comments

• We are building on our scientific leadership in this space and developing a broad pipeline across various targets and modalities, including peptides and small molecules. Leveraging different modalities creates important optionality in our pipeline in terms of potential targets, dosing regimens and scalability.
• Septerna has demonstrated strong capabilities in GPCR drug discovery, and we are excited about the opportunity to develop oral small molecule medicines directed at multiple targets.
• Novo Nordisk has a long-standing track record of bringing transformative therapies to market, particularly in the field of metabolic disease, which makes them the ideal partner to advance a suite of programmes targeting critical GPCRs for treating obesity, type 2 diabetes and other related conditions.
• This collaboration provides a significant opportunity to create multiple potentially groundbreaking oral medicines, while also providing Septerna with the operational flexibility and resources to advance our diverse portfolio of other GPCR-targeted programmes.

Industry Context

The collaboration with Novo Nordisk, a leading global healthcare company with a strong focus on obesity and diabetes, significantly validates Septerna's proprietary Native Complex Platform for GPCR drug discovery. This partnership positions Septerna to address a substantial untapped opportunity in the GPCR target class, which historically accounts for approximately one-third of all FDA-approved drugs, by developing novel oral small molecule therapies for metabolic-related diseases. The focus on GLP-1, GIP, and glucagon receptors aligns with current industry trends emphasizing multi-targeted approaches for complex metabolic conditions like obesity and type 2 diabetes, where there is significant unmet medical need and market potential.

Comparison to Industry Standards

• Septerna's Native Complex Platform aims to unlock the full potential of GPCR therapies by replicating natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale, a unique approach in the industry.
• The collaboration with Novo Nordisk, a leader in metabolic diseases (e.g., Ozempic, Wegovy), provides strong validation for Septerna's platform and pipeline, indicating a high level of confidence from a major pharmaceutical player.
• The financial terms of the Novo Nordisk deal, including a $195 million upfront payment and potential milestones up to $498 million per program, are substantial for a biotech company at Septerna's stage, reflecting the perceived value and potential of its technology and targets.
• The discontinuation of the SEP-786 clinical study, while a setback, is a common occurrence in early-stage drug development and allows for reallocation of resources to more promising programs, a standard practice in the biotech industry to optimize pipeline efficiency.

Legal Proceedings

• The company is not currently a party to any legal proceeding that is expected to have a material adverse effect on its business, financial condition, or liquidity and results of operations.

Related Party Transactions

• The company has a service agreement with Third Rock Ventures, LLC (TRV), a holder of more than 5% of the company's outstanding capital stock, for consulting services. No fees were incurred for Q2 2025, and $0.1 million for the six months ended June 30, 2025.
• A separate consulting agreement was entered into in December 2024 with a former interim Chief Medical Officer affiliated with TRV; total fees incurred were immaterial for Q2 2025 and $0.1 million for the six months ended June 30, 2025.

Stakeholder Impact

• **Shareholders**: The Novo Nordisk collaboration provides significant non-dilutive funding and validates the company's platform, potentially increasing shareholder value and reducing future dilution risk. The extended cash runway to 2029 offers greater financial stability.
• **Employees**: Increased headcount in R&D and G&A functions indicates growth and potential for new opportunities. The collaboration secures funding for ongoing and future research programs, providing job security and opportunities for scientific advancement.
• **Customers/Patients**: The collaboration aims to develop multiple oral small molecule therapies for metabolic-related diseases, potentially leading to new treatment options for patients with significant unmet needs.
• **Creditors**: The extended cash runway and significant upfront payment from Novo Nordisk improve the company's financial health and ability to meet its obligations, reducing credit risk.

Next Steps

• Advance SEP-631 (MRGPRX2) into clinical development.
• Continue to advance next-generation oral small molecule PTH1R agonists from the PTH1R program toward clinical development.
• Continue to advance other programs in the pipeline.
• Conduct four simultaneous research and development programs with Novo Nordisk for metabolic-related diseases, targeting GLP-1, GIP, and glucagon receptors.
• Novo Nordisk will be responsible for all global development and commercialization for product candidates from IND-enabling activities onwards.
• Evaluate the impact of the One Big Beautiful Bill Act (H.R.1) on condensed financial statements.

Key Dates

Recommendation

The transformative collaboration with Novo Nordisk is a game-changer for Septerna, providing substantial non-dilutive funding ($195 million upfront, potential multi-billion dollar milestones) and validating its proprietary Native Complex Platform. This significantly de-risks the company's financial position, extending its cash runway to at least 2029, which is critical for a development-stage biotech. While current period losses increased, this is expected as the company scales its R&D. The strategic partnership with a leader in metabolic diseases positions Septerna for long-term growth and potential breakthroughs in a high-value therapeutic area, making it a highly attractive investment.

Keywords

Biotechnology, GPCR, G protein-coupled receptor, Drug Discovery, Native Complex Platform, Novo Nordisk, Collaboration, Metabolic Diseases, Obesity, Type 2 Diabetes, Endocrinology, Immunology, Inflammation, SEC Filing, 10-Q, Clinical Trials, Preclinical Studies, Pharmaceuticals